Triggering with HCG or GnRH agonist in GnRH antagonist treated oocyte donation cycles: a randomised clinical trial.

Galindo A, Bodri D, Guillén JJ, Colodrón M, Vernaeve V, Coll O

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology1 Jan 2009Cited by 55 (Europe PMC)

PMID19165664DOI10.1080/09513590802404013PepBankPUB-19165664

Publisher page PubMedAsk about this study

Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
In oocyte donors, triptorelin and recombinant hCG produced comparable numbers of retrieved cumulus-oocyte complexes.
In plain wordsIn oocyte donors, triptorelin and recombinant hCG produced comparable numbers of retrieved cumulus-oocyte complexes.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeRetrieved cumulus-oocyte complexes
Study
n = 212
Comparator
Recombinant hCG
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.2 mgAs given in this study (human).
Measurements
Retrieved COCs
12 COCs
recombinant hCG (first-listed group)
Retrieved COCs
11.4 COCs
triptorelin (second-listed group)
Source sentences
Summary
The number of retrieved COCs (12 +/- 6.3 vs 11.4 +/- 6.4), mature oocytes (8 +/- 4.6 vs 7.5 +/- 4.1), the proportion of mature oocytes (67.2 +/- 20.4% vs 67.1 +/- 20.9%) and fertilisation rates (67.8 +/- 23.5% vs 71.1 +/- 22.1%) were comparable.
1 context sentence(design, population, supporting numbers)
Summary · context
After stimulation with 225 IU rFSH and Cetrorelix 0.25 mg/day, 212 oocyte donors were randomised with sealed envelopes for triggering with recombinant hCG (Ovitrelle 250 microgr, n = 106) or a GnRH agonist (triptorelin 0.2 mg, n = 106).
Report a problemFND-1916566401
02HumanRandomized controlled trialEfficacy outcome
In oocyte donors, triptorelin and recombinant hCG produced comparable numbers of mature oocytes.
In plain wordsIn oocyte donors, triptorelin and recombinant hCG produced comparable numbers of mature oocytes.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeMature oocyte number
Study
n = 212
Comparator
Recombinant hCG
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.2 mgAs given in this study (human).
Measurements
Mature oocytes
8 oocytes
recombinant hCG (first-listed group)
Mature oocytes
7.5 oocytes
triptorelin (second-listed group)
Source sentences
Summary
The number of retrieved COCs (12 +/- 6.3 vs 11.4 +/- 6.4), mature oocytes (8 +/- 4.6 vs 7.5 +/- 4.1), the proportion of mature oocytes (67.2 +/- 20.4% vs 67.1 +/- 20.9%) and fertilisation rates (67.8 +/- 23.5% vs 71.1 +/- 22.1%) were comparable.
1 context sentence(design, population, supporting numbers)
Summary · context
After stimulation with 225 IU rFSH and Cetrorelix 0.25 mg/day, 212 oocyte donors were randomised with sealed envelopes for triggering with recombinant hCG (Ovitrelle 250 microgr, n = 106) or a GnRH agonist (triptorelin 0.2 mg, n = 106).
Report a problemFND-1916566402
03HumanRandomized controlled trialEfficacy outcome
In oocyte donors, triptorelin and recombinant hCG produced comparable proportions of mature oocytes.
In plain wordsIn oocyte donors, triptorelin and recombinant hCG produced comparable proportions of mature oocytes.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeMature oocyte proportion
Study
n = 212
Comparator
Recombinant hCG
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.2 mgAs given in this study (human).
Measurements
Proportion of mature oocytes
67.2%
recombinant hCG (first-listed group)
Proportion of mature oocytes
67.1%
triptorelin (second-listed group)
Source sentences
Summary
The number of retrieved COCs (12 +/- 6.3 vs 11.4 +/- 6.4), mature oocytes (8 +/- 4.6 vs 7.5 +/- 4.1), the proportion of mature oocytes (67.2 +/- 20.4% vs 67.1 +/- 20.9%) and fertilisation rates (67.8 +/- 23.5% vs 71.1 +/- 22.1%) were comparable.
1 context sentence(design, population, supporting numbers)
Summary · context
After stimulation with 225 IU rFSH and Cetrorelix 0.25 mg/day, 212 oocyte donors were randomised with sealed envelopes for triggering with recombinant hCG (Ovitrelle 250 microgr, n = 106) or a GnRH agonist (triptorelin 0.2 mg, n = 106).
Report a problemFND-1916566403
04HumanRandomized controlled trialEfficacy outcome
In oocyte donors, triptorelin and recombinant hCG produced comparable fertilization rates.
In plain wordsIn oocyte donors, triptorelin and recombinant hCG produced comparable fertilization rates.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeFertilization rate
Study
n = 212
Comparator
Recombinant hCG
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.2 mgAs given in this study (human).
Measurements
Fertilization rate
67.8%
recombinant hCG (first-listed group)
Fertilization rate
71.1%
triptorelin (second-listed group)
Source sentences
Summary
The number of retrieved COCs (12 +/- 6.3 vs 11.4 +/- 6.4), mature oocytes (8 +/- 4.6 vs 7.5 +/- 4.1), the proportion of mature oocytes (67.2 +/- 20.4% vs 67.1 +/- 20.9%) and fertilisation rates (67.8 +/- 23.5% vs 71.1 +/- 22.1%) were comparable.
1 context sentence(design, population, supporting numbers)
Summary · context
After stimulation with 225 IU rFSH and Cetrorelix 0.25 mg/day, 212 oocyte donors were randomised with sealed envelopes for triggering with recombinant hCG (Ovitrelle 250 microgr, n = 106) or a GnRH agonist (triptorelin 0.2 mg, n = 106).
Report a problemFND-1916566404
05HumanRandomized controlled trialSafety outcome
In oocyte donors, no mild OHSS occurred with triptorelin, versus nine cases with hCG.
In plain wordsIn oocyte donors, no mild OHSS occurred with triptorelin, versus nine cases with hCG.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseMild OHSS
Study
n = 212
Comparator
Recombinant hCG
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
0.2 mgAs given in this study (human).
Measurements
Mild OHSS cases
9 cases
hCG group
Source sentences
Summary
Nine cases of mild and one case of severe OHSS occurred in hCG group, whereas no cases were detected in GnRH agonist group.
1 context sentence(design, population, supporting numbers)
Summary · context
After stimulation with 225 IU rFSH and Cetrorelix 0.25 mg/day, 212 oocyte donors were randomised with sealed envelopes for triggering with recombinant hCG (Ovitrelle 250 microgr, n = 106) or a GnRH agonist (triptorelin 0.2 mg, n = 106).
Report a problemFND-1916566408
06HumanRandomized controlled trialSafety outcome
In oocyte donors, no severe OHSS occurred with triptorelin, versus one case with hCG.
In plain wordsIn oocyte donors, no severe OHSS occurred with triptorelin, versus one case with hCG.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseSevere OHSS
Study
n = 212
Comparator
Recombinant hCG
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
0.2 mgAs given in this study (human).
Measurements
Severe OHSS cases
1 cases
hCG group
Source sentences
Summary
Nine cases of mild and one case of severe OHSS occurred in hCG group, whereas no cases were detected in GnRH agonist group.
1 context sentence(design, population, supporting numbers)
Summary · context
After stimulation with 225 IU rFSH and Cetrorelix 0.25 mg/day, 212 oocyte donors were randomised with sealed envelopes for triggering with recombinant hCG (Ovitrelle 250 microgr, n = 106) or a GnRH agonist (triptorelin 0.2 mg, n = 106).
Report a problemFND-1916566409
07HumanRandomized controlled trialEfficacy outcome
In recipients, clinical pregnancy rates did not differ significantly between triptorelin and recombinant hCG donor triggering.
In plain wordsIn recipients, clinical pregnancy rates did not differ significantly between triptorelin and recombinant hCG donor triggering.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeClinical pregnancy rate
Study
n: not reported in source
Comparator
Recombinant hCG
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.2 mgAs given in this study (human).
Source sentences
Summary
Clinical, ongoing pregnancy and live birth rates were not statistically different in the corresponding recipient groups.
1 context sentence(design, population, supporting numbers)
Summary · context
After stimulation with 225 IU rFSH and Cetrorelix 0.25 mg/day, 212 oocyte donors were randomised with sealed envelopes for triggering with recombinant hCG (Ovitrelle 250 microgr, n = 106) or a GnRH agonist (triptorelin 0.2 mg, n = 106).
Report a problemFND-1916566405
08HumanRandomized controlled trialEfficacy outcome
In recipients, ongoing pregnancy rates did not differ significantly between triptorelin and recombinant hCG donor triggering.
In plain wordsIn recipients, ongoing pregnancy rates did not differ significantly between triptorelin and recombinant hCG donor triggering.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeOngoing pregnancy rate
Study
n: not reported in source
Comparator
Recombinant hCG
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.2 mgAs given in this study (human).
Source sentences
Summary
Clinical, ongoing pregnancy and live birth rates were not statistically different in the corresponding recipient groups.
1 context sentence(design, population, supporting numbers)
Summary · context
After stimulation with 225 IU rFSH and Cetrorelix 0.25 mg/day, 212 oocyte donors were randomised with sealed envelopes for triggering with recombinant hCG (Ovitrelle 250 microgr, n = 106) or a GnRH agonist (triptorelin 0.2 mg, n = 106).
Report a problemFND-1916566406
09HumanRandomized controlled trialEfficacy outcome
In recipients, live birth rates did not differ significantly between triptorelin and recombinant hCG donor triggering.
In plain wordsIn recipients, live birth rates did not differ significantly between triptorelin and recombinant hCG donor triggering.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeLive birth rate
Study
n: not reported in source
Comparator
Recombinant hCG
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.2 mgAs given in this study (human).
Source sentences
Summary
Clinical, ongoing pregnancy and live birth rates were not statistically different in the corresponding recipient groups.
1 context sentence(design, population, supporting numbers)
Summary · context
After stimulation with 225 IU rFSH and Cetrorelix 0.25 mg/day, 212 oocyte donors were randomised with sealed envelopes for triggering with recombinant hCG (Ovitrelle 250 microgr, n = 106) or a GnRH agonist (triptorelin 0.2 mg, n = 106).
Report a problemFND-1916566407

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
27 Oct 2026, 16:35 UTC
Study data updated · source update from Europe PMC
Version 2
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.